A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009123/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a prospective randomized, double-blind, placebo-controlled study in participants with
disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
提供机构：
Vivli
创建时间：
2023-07-31
